2023

AUG

09

LimmaTech Biologics will be attending the 23rd International Pathogenic Neisseria Conference in Boston from 24 through 29 September 2023.

AUG

09

LimmaTech Biologics will be attending the Vaccines Europe 2023 in Berlin from 14 through 15 September 2023.

Dr Paula Carranza to present

JUL

20

LimmaTech Biologics Appoints Franz-Werner Haas as CEO to Lead Company into Next Stage of Corporate Growth

LimmaTech has leveraged a novel technology platform to produce a pipeline of vaccines against multi-resistant bacterial infections that present global health threats

JUL

20

GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine

LimmaTech in-licenses Shigella bioconjugate vaccine from GSK to continue its clinical development; Phase I/II study completion and results are expected in 2023

MAY

31

LimmaTech Biologics will be attending the Bio International Convention in Boston from 5 through 8 June 2023.

MAY

10

LimmaTech Biologics will be attending the Bio€quity Europe 2023 in Dublin from 14 through 16 May 2023.

Dr Patricia Martin to present

MAR

15

LimmaTech Biologics will be attending the Swiss Biotech Day in Basel from 24 through 25 April 2023.

Dr Patricia Martin to present

MAR

15

LimmaTech Biologics will be attending the Swiss Nordic Bio 2023 in Zurich on 30 March 2023.

MAR

15

LimmaTech Biologics will be attending the BIO-Europe Spring in Basel from 20 through 22 March 2023.

JAN

13

LimmaTech Biologics will be attending the Vaccines as tools to combat antimicrobial resistance congress in Birmingham from 27 through 28 February 2023.

Dr Cristina Alaimo to present

JAN

13

LimmaTech Biologics will be attending the World Vaccine Congress in Washington from 3 through 6 April 2023.